Opinion|Videos|November 20, 2026

HPV Biology and Rational EGFR Partner Targets

Will Ince, MRCP, FRCR, describes human papillomavirus (HPV)-positive and HPV-negative head and neck squamous cell carcinoma as different diseases.

Will Ince, MRCP, FRCR, describes human papillomavirus (HPV)-positive and HPV-negative head and neck squamous cell carcinoma as different diseases. In HPV-positive disease, the E6 and E7 oncoproteins knock out p53 and the retinoblastoma protein, and APOBEC mutations contribute to an immunologically hot microenvironment. HPV-negative disease almost always carries p53 mutations, with knock-on effects on epidermal growth factor receptor (EGFR) amplification, and is genomically chaotic. Dr. Ince says these features now carry more weight as trial biomarkers. Ross Merkin, MD, compares the second targets of 3 EGFR-directed bispecific or bifunctional antibodies in development. Transforming growth factor beta promotes a fibrotic stroma that keeps immune cells from reaching tumor cells. Leucine-rich repeat-containing G protein-coupled receptor 5 marks cancer stem cells, which chemotherapy spares and which may seed recurrence. Mesenchymal-epithelial transition factor is upregulated with EGFR in more than 90% of HPV-negative tumors and can mediate EGFR resistance. Kevin Harrington, MBBS, PhD, FRCP, FRCR, notes each strategy may interact favorably with immunotherapy.


Related to this article